Huntington Park, California 90255

  • Hypercholesterolemia


The purpose of this placebo-controlled, double-blind study is to assess the effect of several doses of CAT-2054 on LDL-C in hypercholesterolemic patients on a stable dose of high-intensity statin, and to evaluate the safety and tolerability of different doses of CAT-2054 for 4 weeks.


Inclusion Criteria: - Between 18 and 74 years at Screening - Hypercholesterolemia (LDL-C ≥ 70 mg/dL and < 190 mg/dL) plus a stable dose of statin for at least 4 weeks prior to Screening - Satisfies one of the following: 1. Female patients of childbearing potential must have used appropriate and highly effective contraception (a regimen which results in a failure rate of <1% per year) with their partners for 4 weeks prior to Screening, and remain compliant during the treatment phase and until 4 weeks after the last dose of investigational product 2. Male patients must use an acceptable and highly effective contraceptive method during the treatment phase and until 4 weeks after the last dose of investigational product - Body mass index (BMI) ≤45 kg/m2 Exclusion Criteria: - History of any major cardiovascular event (stroke, TIA, MI, PTCI, CABG, hospitalization due to heart failure) within 6 months of Screening - Type I diabetes mellitus or use of insulin - Active peptic ulcer disease or a history of muscle disease or myopathy



Primary Contact:


Backup Contact:


Location Contact:

Huntington Park, California 90255
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: March 26, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.